Clinical Trial Update: A Phase II Trial of a Recombinant Human Anti-Rabies Virus Monoclonal Antibody [Phase 2]

View source ↗

Summary

Phase II trial of a recombinant human anti-rabies monoclonal antibody is not yet recruiting, indicating early-stage development for rabies prevention.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rabies

Drugs mentioned

• Recombinant human anti-rabies monoclonal antibody (anti-rabies monoclonal antibody)

Snippet

Sponsor: Lanzhou Institute of Biological Products Co., Ltd | Conditions: Rabies (Healthy Volunteers) | Phase 2 | Status: NOT_YET_RECRUITING